<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04564690</url>
  </required_header>
  <id_info>
    <org_study_id>#KK.01.1.1.01.0010</org_study_id>
    <nct_id>NCT04564690</nct_id>
  </id_info>
  <brief_title>Enriched QUARTET® Hen Eggs and Cardiovascular Function</brief_title>
  <official_title>Effect of Enriched QUARTET® Hen Eggs on Cardiovascular Function in Cardiovascular Patients and Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Josip Juraj Strossmayer University of Osijek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Josip Juraj Strossmayer University of Osijek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Role of oxidative stress in the development of cardiovascular diseases is well known and&#xD;
      extensively investigated, because of its direct effects on vascular function, but also on the&#xD;
      activation of the immune response. Thus, food products that could increase the antioxidant&#xD;
      capacity of the vascular system would also act protective against cardiovascular diseases.&#xD;
      However, we lack systematic clinical and pre-clinical research with food products instead of&#xD;
      food supplements, which would result in consistent and repeatable results. Many studies have&#xD;
      proven the effectiveness of n-3 polyunsaturated fatty acids (n-3 PUFA) in improvement of&#xD;
      endothelial function, improvement of elasticity of the vascular wall and the&#xD;
      anti-inflammatory effects in patients with chronic diseases, such as metabolic syndrome, if&#xD;
      they are taken as an pharmacological preparation. Our research group recently reported that&#xD;
      favorable anti-inflammatory properties of n-3 PUFA enriched hen eggs potentially contribute&#xD;
      to the improvement of microvascular endothelium-dependent vasodilation in healthy&#xD;
      individuals. In addition, this study aimed to determine the effect of QUARTET® hen eggs&#xD;
      (enriched in n-3 PUFA, selenium, vitamin E and lutein; QUARTET No. 012743696, 2014.)&#xD;
      consumption on cardiovascular function in both healthy individuals and cardiovascular&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular reactivity</measure>
    <time_frame>3 weeks</time_frame>
    <description>Forearm skin microvascular reactivity in response to: vascular occlusion (post-occlusion reactive hyperemia, PORH); iontophoresis of acetylcholine (endothelium-dependent) and sodium nitroprusside (endothelium-independent); and local thermal hyperemia (LTH, NO-dependent vasodilation), measured by laser Doppler flowmetry (LDF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macrovascular reactivity - FMD of brachial artery</measure>
    <time_frame>3 weeks</time_frame>
    <description>Flow mediated dilation (FMD) of brachial artery measured by ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Macrovascular reactivity - TCD of cerebral blood vessels</measure>
    <time_frame>3 weeks</time_frame>
    <description>Vascular reactivity of cerebral blood vessels measured by transcranial Doppler (TCD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress - thiobarbituric acid reactive substances (TBARS)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of biomarkers of oxidative stress level. Thiobarbituric acid reactive substances (TBARS) - biomarker of lipid peroxidation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress - ferric-reducing ability of plasma (FRAP)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of biomarkers of oxidative stress level. Ferric-reducing ability of plasma (FRAP) - biomarker of plasma antioxidant capacity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress - antioxidative enzymes</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of biomarkers of oxidative stress level. Plasma concentration of antioxidative enzymes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T helper lymphocyte differentiation</measure>
    <time_frame>3 weeks</time_frame>
    <description>Regulatory T cells (Treg, Foxp3) and Th17 cells will be determined measuring intracellular expression for distinct Th17 markers by using FACS Canto II flow cytometer system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Pro- and Anti-Inflammatory Cytokines, Chemokines, Growth Factors and Soluble Cell Adhesion Molecules Protein Concentration</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of serum protein concentration (pg/mL) of various pro- and anti-inflammatory cytokines, chemokines, growth factors and soluble cell adhesion molecules by kits and panels for multiplex protein quantitation using the Luminex 200 instrument platform.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial cell activation</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of serum protein concentration of cell adhesion molecules (e.g. intercellular adhesion molecule 1 - ICAM-1, vascular cell adhesion protein 1 - VCAM-1, and E-selectin) by commercially available ELISA kits, or by multiplex assay kits for the Luminex platform (Luminex® 100/200™ System).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measurement of systolic and diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>3 weeks</time_frame>
    <description>Total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>3 weeks</time_frame>
    <description>Body composition and body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg) and Fat (Fat Mass kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fluid status</measure>
    <time_frame>3 weeks</time_frame>
    <description>Body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L) and Body Density (kg/L).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>n-3 Polyunsaturated Fatty Acids</condition>
  <condition>Selenium</condition>
  <condition>Vitamin E</condition>
  <condition>Lutein</condition>
  <arm_group>
    <arm_group_label>QUARTET®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of three QUARTET® (n-3 PUFA, selenium, vitamin E, lutein enriched) hen eggs per day for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consumption of three regular hen eggs per day for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein)</intervention_name>
    <description>Consumption of three QUARTET® hen eggs (enriched in n-3 PUFA, selenium, vitamin E and lutein) per day for three weeks</description>
    <arm_group_label>QUARTET®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Regular hen eggs</intervention_name>
    <description>Consumption of three regular hen eggs per day for three weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers (sedentary)&#xD;
&#xD;
          -  healthy volunteers (athletes)&#xD;
&#xD;
          -  cardiac patients (patients with acute myocardial infarction, hypertensive patients&#xD;
             with/without hypertensive heart disease, heart failure patients)&#xD;
&#xD;
        Exclusion Criteria for Healthy Volunteers:&#xD;
&#xD;
          -  oral contraceptives&#xD;
&#xD;
          -  drugs that could affect endothelium&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  coronary artery disease&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  hyperlipidaemia&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  cerebrovascular and peripheral artery disease&#xD;
&#xD;
        Exclusion Criteria for Cardiac Patients:&#xD;
&#xD;
          -  known malignant disease&#xD;
&#xD;
          -  hereditary metabolic diseases and other hereditary systemic diseases&#xD;
&#xD;
          -  autoimmune diseases or systemic diseases with immunopathology&#xD;
&#xD;
          -  unregulated hypertension&#xD;
&#xD;
          -  recent surgery (3 months)&#xD;
&#xD;
          -  recent significant trauma (6 months)&#xD;
&#xD;
          -  renal insufficiency (except in diabetic patients unless Endogenous Creatinine&#xD;
             Clearance &gt; 60ml / min)&#xD;
&#xD;
          -  active bleeding (hematuria, GI tract, menorrhagia)&#xD;
&#xD;
          -  fresh ICV (6 weeks)&#xD;
&#xD;
          -  neurodegenerative diseases and epilepsy&#xD;
&#xD;
          -  significant anemia (Hg &lt;110 (men), &lt;100 (women))&#xD;
&#xD;
          -  condition after resuscitation (3 months)&#xD;
&#xD;
          -  therapy that significantly affects vascular or immune function (monoclonal antibodies,&#xD;
             immunosuppressants, systemic corticosteroids ...)&#xD;
&#xD;
          -  chronic respiratory failure and conditions of chronic hypoxemia&#xD;
&#xD;
          -  sepsis and chronic active infections with systemic inflammatory response (active&#xD;
             tuberculosis, etc.)&#xD;
&#xD;
          -  untreated thyroid disease&#xD;
&#xD;
          -  active abuse of alcohol and drugs&#xD;
&#xD;
          -  liver failure (advanced liver disease with impaired synthetic and metabolic function)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ines Drenjancevic, MD, PhD</last_name>
    <phone>+385912241406</phone>
    <email>ines.drenjancevic@mefos.hr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientific Center of Excellence for Personalized Health Care, Josip Juraj Strossayer University of Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ines Drenjancevic, MD, PhD</last_name>
      <phone>+385912241406</phone>
      <email>ines.drenjancevic@mefos.hr</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <reference>
    <citation>Stupin A, Rasic L, Matic A, Stupin M, Kralik Z, Kralik G, Grcevic M, Drenjancevic I. Omega-3 polyunsaturated fatty acids-enriched hen eggs consumption enhances microvascular reactivity in young healthy individuals. Appl Physiol Nutr Metab. 2018 Oct;43(10):988-995. doi: 10.1139/apnm-2017-0735. Epub 2018 Apr 10.</citation>
    <PMID>29633621</PMID>
  </reference>
  <reference>
    <citation>Stupin M, Kibel A, Stupin A, Selthofer-Relatić K, Matić A, Mihalj M, Mihaljević Z, Jukić I, Drenjančević I. The Physiological Effect of n-3 Polyunsaturated Fatty Acids (n-3 PUFAs) Intake and Exercise on Hemorheology, Microvascular Function, and Physical Performance in Health and Cardiovascular Diseases; Is There an Interaction of Exercise and Dietary n-3 PUFA Intake? Front Physiol. 2019 Aug 30;10:1129. doi: 10.3389/fphys.2019.01129. eCollection 2019. Review.</citation>
    <PMID>31543828</PMID>
  </reference>
  <reference>
    <citation>Stupin A, Mihalj M, Kolobarić N, Šušnjara P, Kolar L, Mihaljević Z, Matić A, Stupin M, Jukić I, Kralik Z, Grčević M, Kralik G, Šerić V, Drenjančević I. Anti-Inflammatory Potential of n-3 Polyunsaturated Fatty Acids Enriched Hen Eggs Consumption in Improving Microvascular Endothelial Function of Healthy Individuals-Clinical Trial. Int J Mol Sci. 2020 Jun 10;21(11). pii: E4149. doi: 10.3390/ijms21114149.</citation>
    <PMID>32532035</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Josip Juraj Strossmayer University of Osijek</investigator_affiliation>
    <investigator_full_name>Ines Drenjancevic</investigator_full_name>
    <investigator_title>Head of Scientific center of excellence for personalized health care</investigator_title>
  </responsible_party>
  <keyword>n-3 polyunsaturated fatty acids</keyword>
  <keyword>selenium</keyword>
  <keyword>vitamin E</keyword>
  <keyword>lutein</keyword>
  <keyword>vascular function</keyword>
  <keyword>endothelium</keyword>
  <keyword>cardiovascular health</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

